208 related articles for article (PubMed ID: 12431074)
21. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Wang S; Wang Z; Grant S
Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
[TBL] [Abstract][Full Text] [Related]
22. Effects of bryostatin 1, a novel anticancer agent, on intestinal transport and barrier function: role of protein kinase C.
Farokhzad OC; Mun EC; Sicklick JK; Smith JA; Matthews JB
Surgery; 1998 Aug; 124(2):380-6; discussion 386-7. PubMed ID: 9706162
[TBL] [Abstract][Full Text] [Related]
23. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
[TBL] [Abstract][Full Text] [Related]
24. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.
De Lorenzo MS; Yamaguchi K; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Oct; 9(13):5036-43. PubMed ID: 14581379
[TBL] [Abstract][Full Text] [Related]
25. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
26. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
27. Binding of [3H]bryostatin 4 to protein kinase C.
Lewin NE; Dell'Aquila ML; Pettit GR; Blumberg PM; Warren BS
Biochem Pharmacol; 1992 May; 43(9):2007-14. PubMed ID: 1596288
[TBL] [Abstract][Full Text] [Related]
28. Control of olefin geometry in the bryostatin B-ring through exploitation of a C(2)-symmetry breaking tactic and a Smith-Tietze coupling reaction.
Hale KJ; Hummersone MG; Bhatia GS
Org Lett; 2000 Jul; 2(15):2189-92. PubMed ID: 10930240
[TBL] [Abstract][Full Text] [Related]
29. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.
Hood KA; Bäckström BT; West LM; Northcote PT; Berridge MV; Miller JH
Anticancer Drug Des; 2001; 16(2-3):155-66. PubMed ID: 11962513
[TBL] [Abstract][Full Text] [Related]
30. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
32. Bryostatin-1 attenuates TNF-induced epithelial barrier dysfunction: role of novel PKC isozymes.
Yoo J; Nichols A; Song JC; Mammen J; Calvo I; Worrell RT; Cuppoletti J; Matlin K; Matthews JB
Am J Physiol Gastrointest Liver Physiol; 2003 Apr; 284(4):G703-12. PubMed ID: 12505880
[TBL] [Abstract][Full Text] [Related]
33. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.
Dale IL; Bradshaw TD; Gescher A; Pettit GR
Cancer Res; 1989 Jun; 49(12):3242-5. PubMed ID: 2720677
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.
Kennedy MJ; Prestigiacomo LJ; Tyler G; May WS; Davidson NE
Cancer Res; 1992 Mar; 52(5):1278-83. PubMed ID: 1737390
[TBL] [Abstract][Full Text] [Related]
35. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.
Elgie AW; Sargent JM; Alton P; Peters GJ; Noordhuis P; Williamson CJ; Taylor CG
Leuk Res; 1998 Apr; 22(4):373-8. PubMed ID: 9669842
[TBL] [Abstract][Full Text] [Related]
36. A new synthetic approach to the C ring of known as well as novel bryostatin analogues.
Wender PA; Koehler MF; Sendzik M
Org Lett; 2003 Nov; 5(24):4549-52. PubMed ID: 14627380
[TBL] [Abstract][Full Text] [Related]
37. Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain.
de Vries DJ; Herald CL; Pettit GR; Blumberg PM
Biochem Pharmacol; 1988 Nov; 37(21):4069-73. PubMed ID: 3190746
[TBL] [Abstract][Full Text] [Related]
38. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
39. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase C-alpha but not protein kinase C-epsilon is differentially down-regulated by bryostatin 1 and tetradecanoyl phorbol 13-acetate in SH-SY5Y human neuroblastoma cells.
Jalava A; Lintunen M; Heikkilä J
Biochem Biophys Res Commun; 1993 Mar; 191(2):472-8. PubMed ID: 8461005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
